ETHIC Act

The ETHIC Act would limit patent holders to asserting no more than one patent per "Patent Group" in infringement lawsuits against generic or biosimilar drug applicants or manufacturers, aiming to reduce patent thickets that delay market competition. It applies to drugs approved under the Federal Food, Drug, and Cosmetic Act and biological products licensed under the Public Health Service Act, with the restriction taking effect for applications submitted on or after the bill’s enactment. The bill defines a Patent Group as two or more commonly owned patents or applications linked through disclaimers under patent law, preventing multiple assertions from the same group against a single party.…

No official summary is available here. This one was written by AI from the bill’s text.